Do your literature screening processes meet best practices for regulatory compliance? Are irrelevant references wasting your time and resources? Balancing precision and recall in PV searches is challenging. Discover how our end-to-end solution, combining top biopharma content, advanced technology, and expert services, can streamline your process. Complete the contact form to continue conversations on optimizing your literature screening, here: https://lnkd.in/ekr7z5iM #regulatory #biopharma #dialog #solutions
About us
Think forward™ to a healthier tomorrow. Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. Our connected data, deep expertise and intelligence platforms empower life sciences and healthcare companies to deliver safe, effective and commercially successful treatments to patients faster. Clarivate is home to Cortellis™, solutions for real world data, medtech, market access and commercialization and deep consulting expertise. About Clarivate Clarivate™ is a global leader in providing trusted information and insights to accelerate the pace of innovation. We offer subscription and technology-based solutions coupled with deep domain expertise that cover the entire lifecycle of innovation – from foundational research and ideas to protection and commercialization. Today, we’re setting a trail-blazing course to help customers turn bold ideas into life-changing inventions. Our portfolio consists of some of the world’s most trusted information brands, including the Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor™ and Publons™. For more information, please visit clarivate.com.
- Website
-
https://clarivate.com/industries/life-sciences-and-healthcare/
External link for Clarivate for Life Sciences & Healthcare
- Industry
- IT Services and IT Consulting
- Company size
- 10,001+ employees
- Specialties
- pharmaceuticals, biopharma, pharma, and medtech
Updates
-
A Clarivate study of 10.8 million U.S. adults reveals that the prevalence and co-occurrence of immune-mediated inflammatory diseases like inflammatory bowel disease and rheumatoid arthritis varies by race and ethnicity. While patients face misdiagnosis as well as treatment safety and efficacy challenges, developers are under increasing pressure from regulators like FDA to demonstrate how their products stand to impact diverse populations. Can real world data offer a means of augmenting clinical trials? Can RWD enable comprehensive analysis of a wide range of autoimmune diseases? Read more: https://lnkd.in/eUiGCXXu #diversity #realworlddata #autoimmunedisease
-
Tubulis GmbH, which aims to bring the true therapeutic value of ADCs to patients, is one of the seven innovative companies listed in the Clarivate Companies to Watch report this year. The company combines disease-specific insight with its novel proprietary technologies, including the Tub-tag® and P5 conjugation platforms, to deliver a diverse range of targeting molecules and innovative payloads in ADCs developed in-house as well as by partners. Why is Tubulis a company to watch? Download the report to discover innovations transforming drug discovery and development, revolutionizing cancer treatment, and capturing big pharma interest, here: https://lnkd.in/ezuGNPBk #oncology #cancertreatment #drugdiscovery #pharma
-
Volume-Based Procurement (VBP) in Mainland China has led to seismic changes in the medical technology industry. This policy has had a profound impact on both multinational and domestic companies, necessitating strategic adjustments and re-evaluation of commercial operations. How will this impact the Chinese MedTech market? Clarivate analysts identify the regulatory changes in Mainland China and five key MedTech trends in 2024: shifts in sites of service, AI in MedTech, the impact of GLP-1 receptor agonists, supply chain and deals in MedTech. The report is the second installment in a two-part series offering a predictive analysis of emerging trends shaping the MedTech industry. Learn more: https://lnkd.in/ed96arGe #MedicalTechnologiesToWatch #MedtechTrendsToWatch #MedicalDevices #Medtech #MedicalTechnology
-
A Clarivate study of 10.8 million U.S. adults reveals that the prevalence and co-occurrence of immune-mediated inflammatory diseases like inflammatory bowel disease and rheumatoid arthritis varies by race and ethnicity. While patients face misdiagnosis as well as treatment safety and efficacy challenges, developers are under increasing pressure from regulators like the FDA to demonstrate how their products stand to impact diverse populations. Can real world data offer a means of augmenting clinical trials? Can RWD enable comprehensive analysis of a wide range of autoimmune diseases? Read more: https://lnkd.in/eUiGCXXu #diversity #realworlddata #autoimmunedisease #FDA #RA
-
Clarivate launches the new OFF-X™ platform aiming to deliver crucial drug and target safety intelligence to proactively identify risks. Fully integrated with Cortellis Drug Discovery Intelligence, OFF-X™ provides a comprehensive, one-stop resource for safety information, streamlining processes and enhancing efficiency which ultimately delivers a competitive edge. “By combining our safety intelligence with advanced analytics, we empower clients to accelerate the delivery of safe, effective and commercially successful treatments to patients,” says Justin Hubbard, MD, Vice President, Product Management, Life Sciences and Healthcare at Clarivate. The new platform features an upgraded technology stack and enhanced functionality while retaining its core capabilities including an 80% reduction in loading times for targets and drugs, a clearer visual design, full-screen visualization and additional analytic tools. Learn more: https://lnkd.in/dEZBDwnA #drugsafety #intelligence #analytics
-
How will weight loss and diabetes treatments impact medical technology companies? GLP-1 drugs like semaglutide and tirzepatide spooked investors who feared that these treatments could disrupt a number of medical technologies, including surgical obesity interventions and orthopedics. Read more: https://lnkd.in/gTsVxVCN
-
Real-world data (RWD) is key to gaining a comprehensive understanding of rare diseases, utilizing sources like electronic health records (EHR) and scientific literature. How can the integration of machine learning with RWD reveal hidden patterns and speed up drug development? Read more by Henry Levy here: https://lnkd.in/eacz4WKk #LifeSciences #RWD #RareDiseases #DrugDevelopment #MachineLearning #HealthcareInnovation #Clarivate #RWD
The integration of machine learning (ML) and real-world data (RWD) is gaining momentum, particularly in the field of rare diseases and specialized medicine, offering a powerful tool for the pharmaceutical industry to deliver targeted treatments to patients in need. Recent data from the National Organization for Rare Disorders (NORD), as highlighted in a Clarivate report, reveals a critical reality: over 90% of rare diseases lack an FDA-approved treatment. With an estimated 350 million people worldwide affected by some form of rare disease, including 25-30 million Americans, the urgency to find solutions is clear. Today, RWD represents a crucial asset in providing a comprehensive picture of rare diseases. It allows life science companies to explore epidemiological aspects, drawing data from diverse sources such as electronic health records (EHR) and scientific literature. Simultaneously, applying ML to RWD opens doors to uncovering hidden patterns and associations, generating actionable insights that can accelerate advancements in drug development and commercialization. However, to ensure the success of this approach, it’s fundamental to establish rigorous data management practices, privacy protocols, and ethical standards. These measures are imperative to protect patient confidentiality, uphold data quality and integrity, and mitigate regulatory risks associated with the use of RWD and ML. #Clarivate #Pharma #Healthcare #Innovation #RWD #ML #RareDiseases
-
Diagnostics facilitate preventive measures, such as lifestyle changes or prophylactic treatments, which can prevent the onset of chronic diseases and reduce long-term healthcare costs. They also enable the customization of treatments to individual patients' needs, improving the effectiveness of therapies and overall healthcare economics. Join industry experts Elliott Greenspan, CIO and Co-Founder, Igentify, Lishan Aklog, MD, Chairman and CEO, Lucid Diagnostics, Rollie Carlson, CEO, Immunexpress Inc. and Mike Ward, Head of Thought Leadership for Life Sciences & Healthcare, Clarivate, as they discuss the latest innovations in the field of diagnostics. Watch our on-demand webinar 'New frontiers in diagnostics: opportunities and challenges post-pandemic' to learn more on the potential impact of diagnostics on the industry: https://lnkd.in/d7fxfkN7 #MedTech #Diagnostics #healthcareeconomy
-
Tallac Therapeutics with next-generation ADC technology, is one of the seven innovative companies listed in the Clarivate Companies to Watch report this year. The company's novel antibody-oligonucleotide conjugation technology underpins its pipeline of immunotherapy candidates. These candidates provide targeted immune activation within the tumor microenvironment using a potent Toll-like receptor (TLR9) agonist (T-CpG). Why is Tallac Therapeutics a company to watch? Download the report to discover innovations transforming drug discovery and development, revolutionizing cancer treatment, and capturing big pharma interest, here: https://lnkd.in/eCSaAWtu #oncology #cancertreatement #biotech #pharma #companiestowatch